GlassScriptPhysician profile
Michelle G Barcio
NPI 1851394068
$2,657.70
in general payments reported to CMS, 2019-2025
34 companies · $610 in 2025
The $610 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $65.09 · 2022: $583 · 2023: $595 · 2024: $488 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,693.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $441.30 | 2023-2025 | Veozah |
| Ethicon US, LLC | $271.77 | 2019-2025 | Stratafix, Evarrest, Enseal |
| Sumitomo Pharma America, INC. | $190.60 | 2023-2025 | Myfembree |
| Evofem Biosciences, INC. | $187.91 | 2022-2025 | Phexxi, Solosec, Phexx |
| Medtronic, INC. | $149.39 | 2022 | |
| Exeltis, USA INC. | $129.43 | 2019-2024 | Slynd |
| Myovant Sciences INC. | $118.85 | 2022 | |
| Mayne Pharma Commercial LLC | $102.48 | 2022-2025 | |
| Hologic Sales and Service, LLC | $96.50 | 2019-2025 | Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $96.12 | 2020-2023 | |
| Abbvie INC. | $94.10 | 2022-2023 | Lo Loestrin Fe |
| Organon LLC | $80.16 | 2022-2024 | Nexplanon |
| Biogen, INC. | $80.02 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $77.73 | 2023 | Accrufer |
| Baxter Healthcare | $65.97 | 2024 | Perclot |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $51.81 | 2023 | Exparel |
| Daiichi Sankyo INC. | $39.54 | 2019 | |
| Merck Sharp & Dohme LLC | $38.83 | 2019-2020 | |
| Allergan, INC. | $37.95 | 2019 | |
| Millicent US INC | $35.28 | 2024 | Femring, Intrarosa |
| Lupin INC. | $27.25 | 2019 | |
| Pfizer INC. | $24.55 | 2019-2022 | |
| Zyla Life Sciences, INC. | $24.01 | 2019 | |
| Avion Pharmaceuticals | $22.64 | 2023 | Balcoltra |
| Coopersurgical, INC. | $22.34 | 2025 | Paragard T 380a |
| Smith+Nephew, INC. | $20.97 | 2020 | |
| Mylan Pharmaceuticals INC. | $20.02 | 2022 | |
| Dexcom, INC. | $19.37 | 2025 | Dexcom G6 Transmitter |
| Davol INC. | $18.11 | 2022 | |
| Therapeuticsmd, INC. | $16.35 | 2019 | |
| Exact Sciences Corporation | $16.30 | 2023 | Cologuard Collection Kit |
| Meditrina | $14.85 | 2022 | |
| Olympus America INC. | $13.68 | 2019 | |
| Minerva Surgical, INC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Barcio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.